Nektar Therapeutics (NAS:NKTR)
$ 1.075 -0.105 (-8.9%) Market Cap: 198.29 Mil Enterprise Value: 79.58 Mil PE Ratio: 0 PB Ratio: 3.98 GF Score: 59/100

Nektar Therapeutics Analyst and Investor Call Transcript

Feb 23, 2023 / 10:00PM GMT
Release Date Price: $2.96 (-1.66%)
Operator

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Analyst and Investor Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Vivian Wu. Please go ahead.

Vivian Wu

Thank you, Crystal, and good afternoon, everyone. With us on the call are Howard Robin, our President and CEO; Jill Thomsen, our CFO; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; Dr. Brian Kotzin, our Chief Medical Officer; and Mary Tagliaferri, our Chief Development Drug Officer.

On today's call, we expect to make forward-looking statements regarding our business, including clinical trial enrollments and clinical trial results, timing and plans for future clinical trials, timing and plans for future clinical data presentations, the therapeutic potential of our drug candidates, outcomes and plans for health, authority regulatory actions and decisions, financial guidance and certain other statements regarding the future of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot